1. National guidelines for the diagnosis and treatment of hypertension (fourth revision). Sistemnye Gipertenzii 2010; (3): 5–26. Russian (Национальные рекомендации по диагностике и лечению артерии альной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).
2. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: modern aspects of cardiology. Consilium medicum 2006; 8 (11): 113–117. Russian (Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum 2006; 8 (11): 113–117).
3. Preobrazhenskiy D.V., Sidorenko B.A., Dedova I.S., Shaipova A.M., Tarykina E.V. Lercanidipine – a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 14(20): 1411–1417. Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Шаипова А.М., Тарыкина Е.В. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 14(20): 1411–1417).
4. Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: Short plasma half-life, long duration of action. J Cardiovascul Pharmacol 1997; 29 (suppl 1): S19–S24.
5. McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.
6. Barchielli M., Dolfini E., Farina P. et al. Clinical pharmacokinetics of lercanidipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S1–S15.
7. Testa R., Leonardi A., Tajana A et al. Lercanidipine (Rec 15/2375): a novel 1.4-dihydropyridine calcium antagonist for hypertension. Cardiovascular Drug Reviews 1997; 15(3): 187–219.
8. Omboni S, Zanchetti A, for the Multicenter Study Investigators. Antihypertensive efficacy of lercanidipine at 2.5,5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831–1838.
9. Repine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonists vs a non-calcium antagonists hypertension treatment strategy for patients with coronary artery disease. JAMA 2003; 290: 2805– 2816.
10. Ambrosioni E., Circo A. Activity of lercanidipine administrated in single and repeated doses once daily as monitored over 24 hours in patients with mild to moderate essential hypertension. – J. Cardiovascul. Pharmacol 1997; 29(suppl 2):S16–S20.
11. Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S21– S25.
12. Romito R, Pansini MI, Perticone F et al. Comparative effect of lercandipine, felodipine and nifidipine GTIS on blood pressure and heart rate in patients with mild to moderate arterial hypertension. The Lercandipine in Adults (LEAD) Study. J Clin Hypertens (Greenwich) 2003 J;5(4):249–53.
13. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercandipine, lacidipine and nifedipine_GITS on blood pressure and heart rate in elderly hypertensive patients: the Elderly and LErcandipine (ELLE) study. Archives of gerontology and Geriatrics 2003; 37: 203–212.
14. Barballo M., Sangiorgi G. B. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin Exp Res 2000; 12 (5):375–379.
15. Bang LM, Chapman TM, Goa KL Lercandipine – a review of its efficacy management of hypertension. Drugs 2003; 22: 2449–2472.
16. Fogari R., Mugellini A., Corradi L. et al. Efficacy of lercanidipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J Hypertens 2000;18 (Suppl 2): S65.
17. Speccia G. Saccaggi SP, Chezzi C. et al. Cardiovascular safety of lercanidipine in patients with angina pectoris: a review of six randomized clinical trials. Current Therapeutic Research Clin Exp 2001; 62:3–15.
18. Cesarone M. Pressure and microcirculatory effects of treatment with lercandipine in hypertensive patients and vascular patients with hypertension. Angiol 2000; 8 (Suppl 2):S53–S63.
19. Sabbatini M., Tomassoni D., Amenta F Influence of treatment with Ca2+-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mechanisms of Ageing and Development 2001; 122: 795–809.
20. Vestra MD, Pozza G, Mosca A. et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab Nutr Metab 2004; 17: 259–266.
21. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1):73–80.
22. McClellan K.J., Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60 (5): 1123–1140.
23. Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in comparison and in combination with atenolol in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S31–S35.
24. Sangiorgi G. B. Putignano E., Calcara L., Barbagallo M. Efficacy and tolerability of lercanidipine vs. captopril in patients with mild to moderate hypertension in a double-blind controlled study. J Cardiovascul Pharmacol 1997; 29 (suppl 2): S36–S39.
25. Borghi С., Prandin M.G., Dormi A. et al. The use of lercanidipine can improve the individual tolerability in dihydropyridine calcium blockers in hypertensive patients. J Hypertens 2000; 18 (suppl 2): S155–S156.
26. Leonetti G., Magnani B, Pessina AC et al. Lercandipine: a long acting calcium antagonist. Results of trials in elderly hypertensive patien. J Mollecular and Cellular Cardiol 1998; 30: 254.
